- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06068569
Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers
October 4, 2023 updated by: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Safety, Reactogenicity and Immunogenicity Study of the Vector Vaccine GamCovidVac for the Prevention of Coronavirus (COVID-19) Infection Caused by the SARS-CoV-2 Virus With Altered Antigenic Profile With Participation of Adult Volunteers
Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic profile with participation of adult volunteers
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
The study will include volunteers who meet all the specified criteria:
- Written informed consents to participate in the Study;
- Adult volunteers men and women over 18 years old;
- A negative test result for COVID-19, determined by PCR or express method before the introduction of the investigational medicinal product (IMP);
- Consent to the use of effective methods of contraception during the entire period of participation in the Study;
- A negative pregnancy test based on the results of a urine test at a screening visit (for women with preserved reproductive potential);
- Negative test for the presence of narcotic and psychostimulants in the urine at the screening visit;
- Negative alcohol content test at the screening visit;
- Any vaccination not earlier than the last 30 days before inclusion in the Study;
- No contraindications to vaccination;
- Absence of acute infectious and/or respiratory diseases for at least 14 days prior to inclusion in the Study.
Exclusion Criteria:
Volunteers cannot be included in the Study if there is at least one of the following criteria for non-inclusion:
- No written informed consents to participate in the Study
- Therapy with steroids (with the exception of hormonal contraceptives and/or hormone replacement therapy) and / or immunoglobulins or other blood products that did not end 30 days before inclusion in the Study;
- Therapy with any immunosuppressive drugs completed less than 3 months prior to inclusion in the Study;
- Female volunteers during pregnancy or lactation;
- Acute coronary syndrome or stroke suffered less than one year prior to inclusion in the Study;
- Tuberculosis, chronic systemic infections (according to anamnesis);
- Burdened allergic anamnesis (record of anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis), hypersensitivity or allergic reactions to the administration of immunobiological drugs, known allergic reactions to any of the components of the vaccine or vaccine containing similar components, exacerbation of allergic diseases on the day of inclusion in the Study;
- The presence of neoplasms (ICD codes C00-D09) (according to anamnesis);
- Splenectomy (according to the anamnesis);
- Neutropenia (decrease in the absolute number of neutrophils less than 1000 cells / mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin concentration less than 80 g/l) - 6 month prior to inclusion in the Study (according to the anamnesis);
- Volunteers with an active form of the disease caused by the human immunodeficiency virus, syphilis, hepatitis B and C (according to the anamnesis);
- Anorexia, protein deficiency of any origin;
- Alcoholism and drug addiction (according to the anamnesis);
- Participation in any other clinical trial 90 days prior to the screening;
- Extensive tattoos at the injection sites (deltoid muscle area), which do not allow to assess the local reaction to the introduction of investigational medicinal product (IMP);
- Any other condition of the volunteer of the Study, which, in the opinion of the research physician, may prevent the completion of the study in accordance with the protocol;
- Vaccination against COVID-19 or transmitted coronavirus infection (COVID-19) less than 6 months prior to the screening;
- Multiple administration of the Sputnik V vaccine, Sputnik Lite, or multiple administration of any other COVID-19 vaccine for more than three injections (Sputnik V vaccination plus Sputnik Lite revaccination);
- Inability to read in Russian; inability or unwillingness to understand the essence of the Study;
- Any other conditions that limit the validity of obtaining informed consent or may affect the ability of a volunteer to participate in the Study.
- Staff of research centers (chief researcher and members of the research team) directly involved in the research and their family members.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy patients
Drug: GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile); A total of 50 people will be randomized and receive the study drug (vaccine).
Two intramuscular injections of the investigational medicinal product (IMP) will be performed.
1st injection - component I, 2nd injection - component II.
|
Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed.
1st injection - component I, 2nd injection - component II.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of adverse events (AE)
Time Frame: Within 28 days after administration of the drug
|
Occurrence of adverse events (AE)
|
Within 28 days after administration of the drug
|
Occurrence of serious adverse events (SAEs)
Time Frame: Throughout Study completion, until December 2024
|
Occurrence of serious adverse events (SAEs)
|
Throughout Study completion, until December 2024
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
September 26, 2023
First Submitted That Met QC Criteria
October 4, 2023
First Posted (Actual)
October 5, 2023
Study Record Updates
Last Update Posted (Actual)
October 5, 2023
Last Update Submitted That Met QC Criteria
October 4, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-GamCovidVac/N-2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)
-
Gamaleya Research Institute of Epidemiology and...Not yet recruiting
-
Gamaleya Research Institute of Epidemiology and...Not yet recruiting
-
University Health Network, TorontoCanadian Institutes of Health Research (CIHR); Samuel Lunenfeld Research Institute... and other collaboratorsActive, not recruitingVaccine Response | COVID-19 Virus InfectionCanada
-
Federal Budgetary Research Institution State Research...CompletedCovid19Russian Federation
-
Zhongnan HospitalInstitute of Biotechnology, Academy of Military Medical Sciences, PLA of...Recruiting
-
Federal Budgetary Research Institution State Research...Completed
-
Federal Budgetary Research Institution State Research...Completed
-
CanSino Biologics Inc.Beijing Institute of BiotechnologyTerminated
-
CanSino Biologics Inc.Completed